Publication | Closed Access

1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS

Interim AnalysisDiagnostic VirologyHepatitis CViral HepatitisImmunologyAntiviral TherapyHepatitisVirologyOr 4Dauphine Week 12Antiviral DrugMedicineViral Immunity